Does the media favor ALNY or PTGX?

In the previous week, Alnylam Pharmaceuticals had 2 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 12 mentions for Protagonist Therapeutics. Alnylam Pharmaceuticals' average media sentiment score of 1.12 beat Protagonist Therapeutics' score of 0.61 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BIIB or PTGX?

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Biogen. MarketBeat recorded 12 mentions for Protagonist Therapeutics and 11 mentions for Biogen. Biogen's average media sentiment score of 1.10 beat Protagonist Therapeutics' score of 0.61 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PTGX or INSM?

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Insmed. MarketBeat recorded 12 mentions for Protagonist Therapeutics and 11 mentions for Insmed. Insmed's average media sentiment score of 1.15 beat Protagonist Therapeutics' score of 0.61 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PTGX or BNTX?

In the previous week, BioNTech had 9 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 21 mentions for BioNTech and 12 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.61 beat BioNTech's score of 0.44 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor INCY or PTGX?

In the previous week, Incyte had 7 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 19 mentions for Incyte and 12 mentions for Protagonist Therapeutics. Incyte's average media sentiment score of 0.98 beat Protagonist Therapeutics' score of 0.61 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 9 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Protagonist Therapeutics (PTGX) Competitors

$148.18 +3.02 (+2.08%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$151.44 +3.26 (+2.20%)

As of 09/11/2026 07:30 PM Eastern

Compare

PTGX vs. ALNY, BIIB, INSM, BNTX, and INCY

Should you buy Protagonist Therapeutics stock or one of its competitors? Protagonist Therapeutics's main competitors and comparable companies include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Insmed (INSM), BioNTech (BNTX), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Protagonist Therapeutics compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Protagonist Therapeutics (NASDAQ:PTGX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Alnylam Pharmaceuticals has higher revenue and earnings than Protagonist Therapeutics. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.96	$313.75M	$5.38	46.22
Protagonist Therapeutics	$46.02M	208.36	-$130.15M	$1.03	143.86

Protagonist Therapeutics has a net margin of 29.40% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Protagonist Therapeutics	29.40%	12.03%	11.23%

Alnylam Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

Alnylam Pharmaceuticals currently has a consensus price target of $376.67, suggesting a potential upside of 51.47%. Protagonist Therapeutics has a consensus price target of $147.13, suggesting a potential downside of 0.71%. Given Alnylam Pharmaceuticals' higher probable upside, equities analysts plainly believe Alnylam Pharmaceuticals is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89

In the previous week, Alnylam Pharmaceuticals had 2 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 14 mentions for Alnylam Pharmaceuticals and 12 mentions for Protagonist Therapeutics. Alnylam Pharmaceuticals' average media sentiment score of 1.12 beat Protagonist Therapeutics' score of 0.61 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Alnylam Pharmaceuticals beats Protagonist Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Biogen?

Biogen (NASDAQ:BIIB) and Protagonist Therapeutics (NASDAQ:PTGX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Biogen. MarketBeat recorded 12 mentions for Protagonist Therapeutics and 11 mentions for Biogen. Biogen's average media sentiment score of 1.10 beat Protagonist Therapeutics' score of 0.61 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

Biogen has higher revenue and earnings than Protagonist Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.24	$1.29B	$5.65	38.43
Protagonist Therapeutics	$46.02M	208.36	-$130.15M	$1.03	143.86

87.9% of Biogen shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Biogen presently has a consensus target price of $230.14, suggesting a potential upside of 5.98%. Protagonist Therapeutics has a consensus target price of $147.13, suggesting a potential downside of 0.71%. Given Biogen's higher possible upside, equities research analysts plainly believe Biogen is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89

Protagonist Therapeutics has a net margin of 29.40% compared to Biogen's net margin of 8.32%. Protagonist Therapeutics' return on equity of 12.03% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Protagonist Therapeutics	29.40%	12.03%	11.23%

Summary

Protagonist Therapeutics beats Biogen on 10 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Insmed?

Protagonist Therapeutics (NASDAQ:PTGX) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Protagonist Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market. Comparatively, Insmed has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

Protagonist Therapeutics has a net margin of 29.40% compared to Insmed's net margin of -76.94%. Protagonist Therapeutics' return on equity of 12.03% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Insmed	-76.94%	-123.94%	-44.30%

In the previous week, Protagonist Therapeutics had 1 more articles in the media than Insmed. MarketBeat recorded 12 mentions for Protagonist Therapeutics and 11 mentions for Insmed. Insmed's average media sentiment score of 1.15 beat Protagonist Therapeutics' score of 0.61 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	208.36	-$130.15M	$1.03	143.86
Insmed	$1.14B	24.84	-$1.28B	-$4.11	N/A

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Protagonist Therapeutics presently has a consensus price target of $147.13, indicating a potential downside of 0.71%. Insmed has a consensus price target of $205.52, indicating a potential upside of 58.81%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Protagonist Therapeutics beats Insmed on 11 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to BioNTech?

Protagonist Therapeutics (NASDAQ:PTGX) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Protagonist Therapeutics presently has a consensus target price of $147.13, indicating a potential downside of 0.71%. BioNTech has a consensus target price of $126.00, indicating a potential upside of 30.26%. Given BioNTech's higher probable upside, analysts clearly believe BioNTech is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68

In the previous week, BioNTech had 9 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 21 mentions for BioNTech and 12 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.61 beat BioNTech's score of 0.44 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protagonist Therapeutics has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	208.36	-$130.15M	$1.03	143.86
BioNTech	$2.65B	9.23	-$1.29B	-$7.83	N/A

Protagonist Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market.

Protagonist Therapeutics has a net margin of 29.40% compared to BioNTech's net margin of -63.54%. Protagonist Therapeutics' return on equity of 12.03% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
BioNTech	-63.54%	-6.86%	-6.00%

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Protagonist Therapeutics beats BioNTech on 12 of the 17 factors compared between the two stocks.

How does Protagonist Therapeutics compare to Incyte?

Incyte (NASDAQ:INCY) and Protagonist Therapeutics (NASDAQ:PTGX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Incyte has higher revenue and earnings than Protagonist Therapeutics. Incyte is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.82B	4.23	$1.29B	$7.85	15.47
Protagonist Therapeutics	$46.02M	208.36	-$130.15M	$1.03	143.86

Incyte currently has a consensus target price of $124.05, indicating a potential upside of 2.12%. Protagonist Therapeutics has a consensus target price of $147.13, indicating a potential downside of 0.71%. Given Incyte's higher probable upside, analysts plainly believe Incyte is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89

Protagonist Therapeutics has a net margin of 29.40% compared to Incyte's net margin of 27.71%. Incyte's return on equity of 29.93% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Protagonist Therapeutics	29.40%	12.03%	11.23%

97.0% of Incyte shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Incyte had 7 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 19 mentions for Incyte and 12 mentions for Protagonist Therapeutics. Incyte's average media sentiment score of 0.98 beat Protagonist Therapeutics' score of 0.61 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	9 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

Summary

Incyte beats Protagonist Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Protagonist Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTGX vs. The Competition

Export

Metric	Protagonist Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.39B	$3.86B	$7.16B	$12.73B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	143.87	14.18	274.10	25.29
Price / Sales	208.36	1,482.03	656.00	99.06
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	15.07	15.12	10.33	6.20
Net Income	-$130.15M	-$22.86M	$3.50B	$358.50M
7 Day Performance	1.69%	-4.35%	-3.35%	-2.35%
1 Month Performance	-2.52%	-0.04%	-0.43%	-2.77%
1 Year Performance	151.75%	40.63%	19.21%	7.63%

Protagonist Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTGX Protagonist Therapeutics	1.5511 of 5 stars	$148.18 +2.1%	$147.13 -0.7%	+148.3%	$9.39B	$46.02M	143.87	141	Insider Trade
ALNY Alnylam Pharmaceuticals	4.4566 of 5 stars	$266.11 +0.6%	$386.14 +45.1%	-46.9%	$35.39B	$3.71B	49.46	2,770	Positive News Analyst Forecast
BIIB Biogen	3.2673 of 5 stars	$220.83 -1.6%	$228.50 +3.5%	+45.9%	$33.17B	$9.89B	39.08	7,500	Positive News Analyst Forecast
INSM Insmed	3.4202 of 5 stars	$126.29 -0.3%	$205.52 +62.7%	-11.2%	$27.66B	$606.42M	N/A	1,664	News Coverage Positive News Insider Trade
BNTX BioNTech	4.2591 of 5 stars	$103.76 +0.9%	$127.44 +22.8%	-7.3%	$26.02B	$3.25B	N/A	7,807	Analyst Downgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTGX) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. ALNY, BIIB, INSM, BNTX, and INCY

How does Protagonist Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does Protagonist Therapeutics compare to Biogen?

Summary

How does Protagonist Therapeutics compare to Insmed?

Summary

How does Protagonist Therapeutics compare to BioNTech?

Summary

How does Protagonist Therapeutics compare to Incyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protagonist Therapeutics (PTGX) Competitors

PTGX vs. ALNY, BIIB, INSM, BNTX, and INCY

How does Protagonist Therapeutics compare to Alnylam Pharmaceuticals?

Which has preferable earnings & valuation, ALNY or PTGX?

Is ALNY or PTGX more profitable?

Which has more volatility & risk, ALNY or PTGX?

Do analysts prefer ALNY or PTGX?

Does the media favor ALNY or PTGX?

Do institutionals & insiders have more ownership in ALNY or PTGX?

Summary

How does Protagonist Therapeutics compare to Biogen?

Does the media favor BIIB or PTGX?

Which has more risk and volatility, BIIB or PTGX?

Which has stronger valuation & earnings, BIIB or PTGX?

Do insiders & institutionals have more ownership in BIIB or PTGX?

Do analysts prefer BIIB or PTGX?

Is BIIB or PTGX more profitable?

Summary

How does Protagonist Therapeutics compare to Insmed?

Which has more risk and volatility, PTGX or INSM?

Is PTGX or INSM more profitable?

Does the media refer more to PTGX or INSM?

Which has preferable valuation and earnings, PTGX or INSM?

Do institutionals & insiders believe in PTGX or INSM?

Do analysts recommend PTGX or INSM?

Summary

How does Protagonist Therapeutics compare to BioNTech?

Do analysts rate PTGX or BNTX?

Does the media prefer PTGX or BNTX?

Which has stronger earnings & valuation, PTGX or BNTX?

Which has more volatility & risk, PTGX or BNTX?

Is PTGX or BNTX more profitable?

Do institutionals & insiders hold more shares of PTGX or BNTX?

Summary

How does Protagonist Therapeutics compare to Incyte?

Which has preferable earnings & valuation, INCY or PTGX?

Do analysts recommend INCY or PTGX?

Is INCY or PTGX more profitable?

Do insiders and institutionals believe in INCY or PTGX?

Does the media favor INCY or PTGX?

Which has more volatility & risk, INCY or PTGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTGX vs. The Competition

Protagonist Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools